The IGPA is in Africa for the first time ever — breaking the barriers to medicine access!
The conference provides the perfect platform for networking and interacting with emerging market companies and to learn about opportunities for immediate market entry. Delegates and exhibitors will have the opportunity to meet policy makers to understand how current and future policies may impact on their emerging market business strategies, and how they can best take advantage of these policy changes. If your company wants to play a key role in helping address Africa’s disease burden and enter the African pharmaceutical market, then you should attend the 14th Annual International Generic Pharmaceutical Alliance Conference in Cape Town, South Africa.
The IGPA is an alliance of pharmaceutical industry associations from Canada (CGPA), Europe (EGA), USA (GPhA, India (IPA), Japan (JGPMA) and South Africa (NAPM); and has observer member associations from Brazil, Jordan and Taiwan. The conference will attract delegates from global companies like Teva, Sandoz and Mylan, emerging market companies and leading South African players like Adcock, Cipla and Aspen. This conference provides an ideal platform for companies to interact with emerging market companies.
South Africa offers a progressive IP legislation, having successfully adopted TRIPS flexibilities in its patents law¹. These flexibilities allows for registration of generics prior to patent expiry as well as generic development prior to patent expiry.
Africa has a huge disease burden and international donor agencies and NGO’s like Gates Foundation, Clinton Foundation, PEPFAR and the Global fund have rallied to address the lack of access to medicines. The conference will provide the perfect platform for this issue to be discussed and explored.
Considered the gateway to Africa, South Africa is the ideal host for the first ever African IGPA conference. The South African economy and infrastructure provides a world class financial and legal platform; transportation and logistics infrastructure, allowing international companies to enter the continent ‘directly’.
Focusing on the theme of “breaking barriers to medicine access”, the conference, which runs from 1-3 November 2011, will not only give you first-hand access to all this information but also access to key industry players from both multi-national companies and emerging market companies.
Source: ¹Patents Bill, TRIPS and the Right to Health; Economic and Political Weekly October 27, 2001.
